Profound Medical Celebrates a Game-Changing Milestone in Prostate Care
TORONTO, - Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a pioneering company in the medical device arena, is thrilled to announce a groundbreaking achievement in the realm of prostate disease treatment. The Hong Center, under the skilled leadership of Dr. Y. Mark Hong, has successfully completed its 200th independent TULSA Procedure, marking a historic moment in the medical community and establishing a new model for MRI-guided prostate therapy.
A Transformative Approach to Prostate Treatment
The TULSA Procedure stands out as a clinically proven, advanced treatment that ablates diseased prostate tissue while preserving surrounding structures, offering patients a more effective alternative to traditional surgery or radiation. By utilizing Profound’s TULSA-PRO system, this innovative procedure can be performed within an MRI suite, employing robotic-controlled directional ultrasound to ensure precision and patient safety.
“Dr. Hong’s relentless pursuit of innovation and care for his patients has made him a true pioneer in the field,” remarked Arun Menawat, CEO and Chairman of Profound Medical. “Achieving this milestone of 200 TULSA Procedures is not merely a statistic; it represents countless men who are now thriving cancer-free, thanks to Dr. Hong’s commitment and expertise.”
The Power of Independent Urologic Care
Unlike traditional practices that often require collaboration between urologists and radiologists, Dr. Hong’s independent workflow shows that urologists can safely perform the entire TULSA Procedure — from image planning to ablation — delivering exceptional results. Dr. Hong’s success in utilizing this independent approach demonstrates that high rates of patient safety and satisfaction can be maintained
With extensive experience treating prostate cancer cases, ranging from whole-gland approaches to focal therapy and beyond, Dr. Hong has garnered a reputation for consistently achieving outstanding patient outcomes. His patients often report minimal procedural blood loss and quick recovery times, which allows them to return to their daily activities promptly.
A Vision for the Future of Prostate Disease Treatment
“Having performed hundreds of robotic prostatectomies, I recognized early on the potential of the TULSA Procedure to revolutionize prostate cancer treatment,” Dr. Hong explained. “Our focus on accountability allows us to refine our techniques continually, maximizing patient care while minimizing harm. I believe TULSA could replace radical prostatectomy as the primary treatment option for prostate cancer.”
Dr. Hong's Credentials and Experience
Dr. Hong is among the world’s first board-certified urologists to graduate from a fellowship in Integrative Medicine. He completed his education at Stanford University School of Medicine, followed by surgical training at Brigham and Women’s Hospital and urological residency at Harvard Medical School. His extensive research related to prostate cancer and patient anxiety regarding recurrence has paved the way for better understanding and treatment protocols in the field.
His stature in the medical community is further enhanced by his fellowship in robotic and minimally invasive surgery from George Washington University and his numerous published works in prominent international urological journals.
About Profound Medical Corp.
Profound Medical is at the forefront of medical innovation, specializing in AI-powered, MRI-guided therapies that allow for the incision-free ablation of diseased tissue. At the heart of Profound’s offerings is the TULSA-PRO® system, which combines real-time MRI imaging with AI-enhanced planning. This advanced technology is setting a new standard in the treatment of prostate disease.
Aside from the TULSA Procedure, Profound also commercializes Sonalleve®, an inventive therapeutic platform approved for various conditions, including uterine fibroids and cancer pain management. This innovative approach sets the stage for tremendous growth and expansion in non-invasive treatment modalities, potentially transforming patient care across the board.
Frequently Asked Questions
What is the TULSA Procedure?
The TULSA Procedure is an MRI-guided, robotic-controlled treatment for prostate disease that allows for precise ablation of prostate tissue without incisions or radiation.
Who led the achievement of 200 independent TULSA Procedures?
Dr. Y. Mark Hong, a pioneer in the field, led The Hong Center to achieve this milestone in Scottsdale, showcasing the effectiveness of independent urological care.
How does the TULSA Procedure improve patient outcomes?
By allowing for targeted treatment while preserving surrounding tissue, the TULSA Procedure leads to fewer complications, quick recovery, and maintenance of urinary and sexual function.
What is Profound Medical's mission?
Profound Medical aims to innovate within the medical device industry, developing cutting-edge, AI-driven therapeutic solutions to enhance patient care and recovery.
Are there any other products from Profound Medical?
Yes, in addition to the TULSA Procedure, Profound Medical offers Sonalleve®, a therapeutic platform for treating conditions such as uterine fibroids and osteoid osteoma.
